GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PharmGen Science 004720.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

2,955

+0.17%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩173.07bn

FY2016FY2025

Net income

−₩116.64bn

FY2016FY2025

Free cash flow

₩2.65bn

FY2016FY2025

Shareholders' equity

₩146.30bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩173.07bn₩171.29bn₩166.78bn₩150.93bn₩109.87bn₩96.61bn₩95.14bn₩89.10bn₩79.89bn₩71.55bn
Gross profit₩111.68bn₩108.03bn₩97.87bn₩81.30bn₩60.80bn₩53.60bn₩50.40bn₩46.20bn₩41.25bn₩39.98bn
Research and development₩4.64bn₩4.40bn₩5.12bn₩2.89bn₩2.27bn₩1.11bn₩886.3m₩1.24bn₩985.8m₩694.0m
Operating income₩5.99bn₩10.64bn₩9.13bn—−₩4.94bn₩11.38bn₩1.44bn₩4.99bn₩6.01bn₩4.84bn
Net income−₩116.64bn₩2.79bn₩6.09bn₩70.06bn₩32.47bn₩9.22bn₩302.0m₩4.47bn₩4.32bn₩3.45bn
Diluted earnings per share-10,017.18239.68522.926,016.752,788.19792.0025.93355.19380.85343.65

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩195.41bn₩363.45bn₩335.92bn₩317.39bn₩220.32bn₩135.54bn₩100.03bn₩98.19bn₩68.48bn₩64.30bn
Total liabilities₩49.11bn₩114.02bn₩107.71bn₩110.28bn₩93.39bn₩51.97bn₩43.79bn₩41.35bn₩17.43bn₩27.89bn
Debt——————₩17.60bn₩19.33bn₩457.2m₩10.31bn
Shareholders' equity₩146.30bn₩249.44bn₩228.22bn₩207.12bn₩126.94bn₩83.53bn₩56.10bn₩56.74bn₩50.98bn₩36.44bn
Shares outstanding12m12m12m12m12m12m12m13m11m10m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩5.32bn₩2.38bn₩5.44bn−₩1.29bn₩7.78bn₩2.68bn₩2.52bn₩4.22bn₩1.84bn₩7.75bn
Capital spending−₩2.67bn−₩2.78bn−₩3.29bn−₩11.96bn−₩30.75bn−₩4.34bn−₩6.16bn−₩892.3m−₩1.54bn−₩3.43bn
Free cash flow₩2.65bn−₩399.3m₩2.15bn−₩13.24bn−₩22.97bn−₩1.66bn−₩3.64bn₩3.32bn₩299.8m₩4.32bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩47.72bn₩43.32bn₩42.82bn₩41.51bn₩45.87bn₩42.88bn₩44.23bn₩41.65bn
Gross profit₩31.73bn₩28.44bn₩27.07bn₩27.01bn₩30.87bn₩26.72bn₩28.02bn₩26.83bn
Operating income₩1.80bn₩1.77bn−₩752.7m₩1.37bn₩522.2m₩2.04bn₩2.22bn₩3.06bn
Net income−₩13.58bn−₩987.8m−₩117.51bn−₩2.28bn₩3.86bn−₩725.0m₩3.71bn−₩3.91bn
Diluted earnings per share-1,166.53-84.83-10,092.11-195.68331.60-62.26318.19-336.01
Cash from operations₩5.10bn₩1.63bn₩8.70bn₩1.91bn—−₩3.90bn₩3.40bn₩102.0m
Capital spending−₩403.0m−₩1.98bn−₩900.0m−₩799.0m—−₩417.0m−₩406.0m−₩1.04bn
Free cash flow₩4.69bn−₩352.0m₩7.80bn₩1.11bn—−₩4.31bn₩2.99bn−₩943.0m
Total assets₩184.19bn₩199.06bn₩195.41bn₩331.46bn₩330.87bn₩340.19bn₩363.45bn₩338.12bn
Shareholders' equity₩140.04bn₩150.36bn₩146.30bn₩247.76bn₩245.39bn₩248.65bn₩249.44bn₩230.31bn

Financial ratios

Data as of 12 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Gross margin64.5%63.1%58.7%53.9%55.3%55.5%——————
Operating margin3.5%6.2%5.5%—-4.5%11.8%1.5%—————
Net margin-67.4%1.6%3.7%46.4%29.6%9.5%——————
Return on equity-79.7%1.1%2.7%33.8%25.6%11.0%——————
Return on assets-59.7%0.8%1.8%22.1%14.7%6.8%——————
Free cash flow yield——————24.8%13.5%9.9%37.1%——
Revenue growth1.0%2.7%10.5%37.4%13.7%1.6%——————
Earnings growth-4279.5%-54.2%-91.3%115.8%252.0%2953.9%——————
Current ratio2.85x1.69x1.51x1.03x1.09x1.99x——————
Debt to equity——————0.31x0.34x0.01x0.28x0.16x0.47x
Equity ratio74.9%68.6%67.9%65.3%57.6%61.6%——————
Interest coverage4.30x2.56x2.14x—-2.87x39.30x0.97x—————
R&D as a share of sales2.7%2.6%3.1%1.9%2.1%1.2%——————
Buybacks as a share of market value——————7.4%-10.9%-12.9%———

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.7%12.4%11.1%
Operating income—-12.1%2.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin63.8%60.2%59.1%57.2%
Operating margin4.8%———
Net margin-33.1%-5.7%0.5%1.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-0.417.111.91.13.814.3245.620.830.150.2
Price to sales0.30.30.40.51.11.40.81.01.62.4

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 29 Sept 1993.

  • 10-to-1 reverse split · 9 Dec 2014
  • 1-to-0.58 reverse split · 30 Dec 2009
  • 10-for-1 split · 10 Mar 2006
  • 1.268-for-1 split · 4 Jun 1993

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.